Orthofix also reported net income of $14.0 million for this quarter, up from $10.5 million in the prior year. The company also reported 7 percent growth in net sales for its spine business to $81.8 million, while net sales from its orthopedic business decreased 6 percent to $37.7 million.
During the second quarter, increased adoption of the Trinity Evolution in spine applications led to a 48 percent increase in sales of the regenerative biologics business.
More Articles on Orthopedic Devices:
Minimally Invasive Surgery Market to Reach $35.5B by 2016
MiMedx Revenues Reach $4.9M in 2Q, 153% Increase
China Device Market Expected Grew at 20.5% CAGR From 2006-2011
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
